Queen Mary, University of London

Treatment of pulpal and apical disease: The European Society of Endodontology (ESE) S3-level clinical practice guideline (2023) Duncan HF, Kirkevang LL, Peters OA, El-Karim I, Krastl G, Del Fabbro M, Chong BS, et al. Journal article Slowing Heart Rate Protects Against Pathological Cardiac Hypertrophy (2022) Sebastian S, Weinstein LS, Ludwig A, Munroe P, Tinker A Journal article Neutrophil breaching of the blood vessel pericyte layer during diapedesis requires mast cell-derived IL-17A (2022) Joulia R, Guerrero-Fonseca IM, Girbl T, Coates JA, Stein M, Vazquez-Martinez L, Lynam E, et al. Journal article Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial (2022) Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder R, Lurz P, Lobo MD, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution Prevalence of sport injuries in Olympic combat sports: a cross-sectional study examining one Olympic period (2022) Lambert C, Ritzmann R, Lambert S, Lachmann D, Malliaropoulos NG, Gesslein M, Peters N, Shafizadeh S Journal article The End of Informal E-waste Recycling in Accra, Ghana? (2022) Seidu F, Kaifie A Journal article Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial (2022) Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, et al. Journal article A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy (2022) Buettner FA, Winter S, Stuehler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, et al. Journal article HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution